Takeda leads Asia's acquisitive charge in 2012/13
This article was originally published in Scrip
Executive Summary
Out of a total of 19 corporate acquisition or financing deals completed in Asia over the April 2012-March 2013 period, it comes as no surprise to see Asia's largest homegrown pharma firm, Japan's Takeda, take home the prize for sheer number of transactions.